AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03589235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A Platelet-Rich Fibrin dressing
Description: A Platelet-Rich Fibrin dressing (PRF) will be applied in both donor and receiving sites after the free gingival graft.
Study NCT03589235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A non-eugenol-based dressing
Description: A non-eugenol-based dressing (Coe-Pak™) will be applied in both donor and receiving sites after the free gingival graft.
Study NCT00862017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MSg supplementation
Study NCT00862017 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NaCl supplementation
Study NCT01939041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InMotion3 (IMT)
Description: Participant will practice about 2-5-minute of passive, 25-30-minute of assisted-active, and 3-5-minute of active motions in wrist and forearm respectively. The wrist motions will include flexion, extension, radial deviation, and ulnar deviation. Forearm motions will include supination and pronation. During the practice, a visual display will provide online visual feedback of accuracy and coordination success.
Study NCT02579434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam I.V.
Description: Midazolam I.V. 1mg/ml
Study NCT01939041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-Manu-Track (BMT)
Description: The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
Study NCT01939041 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention (CI)
Description: he control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
Study NCT04227028 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT04227028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given PO
Study NCT02996812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exendin (9-39)
Study NCT01487200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 40 mg
Description: single 3 mL IA injection
Study NCT01487200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 60 mg
Description: single 3 mL IA injection
Study NCT04188951 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Description: Patients will receive 17 cycles of pembrolizumab via IV infusion of 200 mg over a period of 30 minutes, every 3 weeks starting no later than 90 days from the date of salvage head and neck therapy.
Study NCT01487200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA IR 40
Description: single 1 mL IA injection
Study NCT04412954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone + Text Messaging with Health Coach
Description: The program includes (1) use of a free commercially available smartphone application program for 12 months, (2) a wearable Fitbit Charge device that will be provided by the study to monitor active minutes, and (3) one 45-minute behavioral counseling session focused on healthy eating and exercise and (4) personalized text messaging for 6 months by a health coach. The health coach will not send feedback during months 6-12. The intervention will be fully self-directed in these months, as there will be no contact between the 6 months visit and 12-month visit.
Study NCT02085213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyceryl Trinitrate
Study NCT02709850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS ANGPTL3-LRx
Study NCT02581007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;
Study NCT02581007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT02581007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
Study NCT02581007 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplant
Study NCT01298713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20mg daily (1 cap) until unbearable toxicity or progression
Study NCT01298713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20mg daily (1 cap) until unbearable toxicity or progression
Study NCT01298713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10mg daily (2 caps of 5mg) until unbearable toxicity or progression
Study NCT01457261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Radiolabelled salbutamol to be administered as a monodisperse particle via a spinning top aerosol generator or else as a polydisperse mist via a nebuliser or metered dose inhaler.
Study NCT03854786 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oxyjun
Description: Oxyjun is the proprietary single ingredient product containing high concentrated well standardized aqueous extract of Terminalia arjuna.
Study NCT03854786 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pacebo
Description: Methyl Crystalline Cellulose
Study NCT04472247 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Continuous EEG and EMG monitoring, with derived variables
Description: All patients are monitored during their ICU stay by frontal EEG and EMG measuring devides, which are already in clinical use.
Study NCT03591939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: role of T- regulatory cells in the patients of diabetic nephropathy
Study NCT01534923 — intervention group
Intervention type: BEHAVIORAL
Intervention: surveys
Description: The intervention will be the audio-recording of the physician-patient consultation, patient and doctor surveys. These audio recordings will be coded. It will also include follow-up phone calls with patients.
Study NCT00395174 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccination
Description: 0.5mL dose for intramuscular injection
Study NCT00395174 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccination
Description: 0.5mL dose for intramuscular injection
Study NCT02700711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
Study NCT02700711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
Study NCT02700711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
Study NCT02700711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
Study NCT02700711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: The pharmacodynamic effects of duloxetine will be determined during maintenance on placebo and methylphenidate
Study NCT04610463 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac flow measurement
Description: Catheterized hemodynamics evaluation - a measurement of systemic flow and pulmonary flow, R-L shunt, L-R shunt using the INNTHERM® system, prior to PFO closure using a common PFO-occluder (within one catheterization intervention).
Study NCT01295866 — intervention group
Intervention type: DEVICE
Intervention: nasal nitric oxide
Study NCT04129320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: enoblituzumab
Description: anti-B7-H3 antibody
Study NCT04129320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGA012
Description: anti-PD-1 antibody
Study NCT04129320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD013
Description: PD-1 X LAG-3 bispecific DART protein
Study NCT00999648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial trigger point pressure release (deactivation)
Description: The deactivation of MTP will be performed always by the same physiotherapist researcher using the same technique. Afterwards, a myofascial maneuver is performed in each treated muscle. All patients of the experimental group will be advised to perform complimentary procedures at home during the 10-week period treatment in order to maintain the status of the muscle up to the next session and to avoid losing the obtained result:(1) Stretching of the treated muscles, once a day for 25 seconds each, (2)Superficial heat in each treated muscle, once a day for 20 minutes, (3) Watch the correct postures during daily activities and sleeping.
Study NCT00999648 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo myofascial trigger point pressure release
Description: The physiotherapist researcher will press in an adjacent nontender muscle fibers of the same muscle that have MTP about 3cm to the right or to the left of each diagnosed MTP, using just a slight pressure on it, not enough for deactivation.
Study NCT01684137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Joalis Bambi Analerg
Study NCT01684137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Joalis Bambi Bronchi
Study NCT01684137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Joalis Bambi Analerg
Study NCT01684137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic Joalis Bambi Bronchi
Study NCT01790035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGG
Study NCT01790035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02212912 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: improvement intervention
Description: Evidence-based clinical pathway: It contained general guideline-based recommendations about acute stroke management. Standard operating procedures (SOP) of performance indicators. A quality coordinator:The role of the quality coordinator includes interacting with physicians once gaps in the incorporation of evidence-based interventions are identified, ensuring that all components of the quality improvement intervention are being used for every acute ischemic stroke (AIS) patient.Monitoring and feedback system of performance measures.~The system could view the level of implementation of prespecified performance measures at any time (per week recommended) , compare with the previous record of own study site and level of other clusters.
Study NCT01961193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contact lens
Description: A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
Study NCT01961193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: punctal plug
Description: A punctal plug will be inserted into each eye. Lubricant drops ethylcellulose) will be instilled four times daily into each eye. The punctal plug will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
Study NCT00565045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulator
Description: Intervention Characteristics Common to Both Groups~• 6-week intervention~1. Home exercise, daily~   1. Exercise (at home) 2 sessions/day~  2. A session consists of 3 (for CCFES) or 4 (for cNMES) 15-min sets separated by 5 min rest~  3. A set entails hand opening, closing, and relaxing in response or synchrony to light and sound cues and according to group-specific instructions~2. Lab therapy, 2x/week~   1. Two 1.5-hr sessions/week, working on functional hand tasks and tracking task (if possible).
Study NCT00565045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical stimulator
Description: Intervention Characteristics Common to Both Groups~• 6-week intervention~1. Home exercise, daily~   1. Exercise (at home) 2 sessions/day~  2. A session consists of 3 (for CCFES) or 4 (for cNMES) 15-min sets separated by 5 min rest~  3. A set entails hand opening, closing, and relaxing in response or synchrony to light and sound cues and according to group-specific instructions~2. Lab therapy, 2x/week~   1. Two 1.5-hr sessions/week, working on functional hand tasks and tracking task (if possible).
Study NCT03193203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg/mL PFS and AI
Study NCT03039140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend weekly educational sessions
Study NCT03039140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in CR program
Study NCT03039140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03039140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02851095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]
Description: Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
Study NCT02851095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
Study NCT02851095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release (XR)
Description: Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
Study NCT03606499 — intervention group
Intervention type: DRUG
Intervention: Ustekinumab
Description: No study treatment will be administered as a part of this study. Participants who are initiating the treatment with ustekinumab, will be observed according to standard clinical practice.
Study NCT02803632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Study NCT02803632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: actigraphic recording
Study NCT03384238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Imaging
Description: Undergo fluorescence imaging
Study NCT02709850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9%NaCl, water, riboflavin
Study NCT02212912 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: no intervention
Description: No intervention indicated that the physicians among control hospital provide routine
Study NCT04385966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block
Description: Interscalene brachial plexus block is a locorregional anaesthesia technique which is indicated in shoulder and upper arm surgery. The goal of this block is to place the needle in the tissue space between the anterior and middle scalene muscles and inject local anesthetic until the spread around the brachial plexus is documented by ultrasound.
Study NCT04385966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Interscalene brachial plexus block is a locorregional anaesthesia technique which is indicated in shoulder and upper arm surgery. The goal of this block is to place the needle in the tissue space between the anterior and middle scalene muscles and inject local anesthetic until the spread around the brachial plexus is documented by ultrasound.
Study NCT04385966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine Hydrochloride 2.5 MG/ML
Description: Levobupivacaine Hydrochloride 2.5 MG/ML is an anesthestic product intended for epidural, intradural and perineural administration. Levobupivacaine is chemically described as (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride. It is a white crystalline powder with a molecular formula of C18H28N2O. HCl, with a molecular weight 324.9.~FDA approval: NDA-20997 (1999).
Study NCT04385966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride 2.5 MG/ML
Description: Levobupivacaine Hydrochloride 2.5 MG/ML is an anesthestic product intended for epidural, intradural and perineural administration. Levobupivacaine is chemically described as (S)-l-butyl-2-piperidylformo-2',6'-xylidide hydrochloride. It is a white crystalline powder with a molecular formula of C18H28N2O. HCl, with a molecular weight 324.9.~FDA approval: NDA-20997 (1999).
Study NCT05417503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation bi-level
Description: For the NIV intervention, two levels of positive airway pressure (bi-level) were used: the positive inspiratory airway pressure (IPAP) was fixed at 6 cmH2O (centimeters of water), which could be gradually increased up to 14 cmH2O (2 cmH2O every minute), depending on the patient's comfort. and gradually increased to 14 cmH2O (2 cmH2O every minute), While the expiratory airway pressure (EPAP) was set at 3 cmH2O, it could be gradually increased up to 7 cmH2O (1 cmH2O every minute), depending on the patient's comfort.while expiratory airway pressure (EPAP) was fixed at 3 cmH2O and gradually increased to 7 cmH2O (1 cmH2O every minute).
Study NCT05417503 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-invasive ventilation placebo
Description: The same pressure chosen by the subject during adaptation was used in the placebo intervention; however, a T tube was connected between the equipment and the circuit, creating a leak and leaving the circuit open. The tube characteristics were: 22 x 18 x 22 mm nebulizer T-connector.
Study NCT00700609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment Based Family therapy (ABFT)
Description: Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.
Study NCT00700609 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attachment Based Family therapy (ABFT)
Description: Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.
Study NCT01377675 — intervention group
Intervention type: OTHER
Intervention: Education
Description: The third year internal medicine residents completed the usual curriculum for COPD and took one pretest and two posttests to validate the questions.
Study NCT03073395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]P16-093
Description: Imaging by Positron Emission Tomography after iv injection of \[68Ga\]P16-093
Study NCT02123212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mailer
Description: Henry Ford intentifies patients meeting birth cohort screening criteria and then sends mailers to those individuals. Mailers contained HCV guidelines, the importance of screening, laboratory slips and locations for patients to act directly on their own behalf. If patients do not respond to the initial mailer, Henry Ford sends additional mailers.
Study NCT02123212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-person recruitment
Description: UAB used study coordinators to actively screen and recruit patients who met the inclusion criteria for birth-cohort screening. Study coordinators were located at two internal medicine clinics, where they approached eligible participants in person. A control group was pulled from an additional two internal medicine clinics, which screened using a risk-based strategy. A cross-over approach was used, so that the intervention and control clinics switched at the midpoint of data collection, allowing all four clinics to participate in both arms of the study.